

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-447US

In Re Application Of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,410	10/22/04	TBA	26,815	TBA	5430

Title:
PROCESS FOR THE PREPARATION OF AMORPHOUS ROSUVASTATIN CALCIUM

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-447US

In Re Application of: **KUMAR et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,410	10/22/04	TBA	26,815	TBA	5430

Title:
PROCESS FOR THE PREPARATION OF AMORPHOUS ROSUVASTATIN CALCIUM

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912
as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

(Date)

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: **March 19, 2007**

William D. Hare
Reg. No. 44,739
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540

cc:

INFORMATION DISCLOSURE CITATION	Docket No.: RLL-447US	Serial No.: 10/576,410
	Applicants: KUMAR <i>et al.</i>	
	Filed: 4/20/2006	Group:

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,260,440	11/9/1993	Hirai <i>et al.</i>	544	322	
	A2	6,589,959	7/8/2003	Taylor	514	275	
	A3	RE 37,314	8/7/2001	Hirai <i>et al.</i>	514	316	

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	WO 01/60804	8/23/2001	PCT	C07D	239/42	
	B2	WO 03/016317	2/27/2003	PCT	C07F	3/04	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C1	Hancock and Zografi, "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems", <i>Journal of Pharmaceutical Sciences</i> , <u>86</u> (1):1-12 (1997)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	